effect overlay
activetrials
Dementia
Dementia
RETHINK

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects With Mild-to-Moderate Alzheimer’s Disease
 

HREC: 2022.215
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lesley-Anne Attard
Funding: Commercial